Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation
- 1 September 2011
- journal article
- Published by Elsevier BV in Kidney International Supplements
- Vol. 1 (4), 136-141
- https://doi.org/10.1038/kisup.2011.30
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trialThe Lancet, 2010
- Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortalityThe Journal of Steroid Biochemistry and Molecular Biology, 2010
- Update in Vitamin DJournal of Clinical Endocrinology & Metabolism, 2010
- 25-Hydroxyvitamin D Levels, Race, and the Progression of Kidney DiseaseJournal of the American Society of Nephrology, 2009
- Vitamin D compounds for people with chronic kidney disease requiring dialysisEmergencias, 2009
- Vitamin D compounds for people with chronic kidney disease not requiring dialysisEmergencias, 2009
- 25-Hydroxyvitamin D Levels and the Risk of Mortality in the General PopulationArchives of Internal Medicine, 2008
- Vitamin D2 Is as Effective as Vitamin D3 in Maintaining Circulating Concentrations of 25-Hydroxyvitamin DJournal of Clinical Endocrinology & Metabolism, 2008
- Vitamin D Supplementation and Total MortalityA Meta-analysis of Randomized Controlled TrialsArchives of Internal Medicine, 2007
- Vitamin D DeficiencyThe New England Journal of Medicine, 2007